Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash from Operations: 2023-2025

Historic Cash from Operations for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$41.1 million.

  • Zenas BioPharma's Cash from Operations fell 32.41% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.5 million, marking a year-over-year decrease of 64.19%. This contributed to the annual value of -$119.7 million for FY2024, which is 292.00% down from last year.
  • Per Zenas BioPharma's latest filing, its Cash from Operations stood at -$41.1 million for Q3 2025, which was up 1.48% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Cash from Operations registered a high of -$15.4 million during Q4 2023, and its lowest value of -$41.7 million during Q2 2025.
  • In the last 3 years, Zenas BioPharma's Cash from Operations had a median value of -$34.1 million in 2024 and averaged -$31.9 million.
  • Data for Zenas BioPharma's Cash from Operations shows a maximum YoY plummeted of 150.35% (in 2024) over the last 5 years.
  • Zenas BioPharma's Cash from Operations (Quarterly) stood at -$15.4 million in 2023, then slumped by 150.35% to -$38.6 million in 2024, then slumped by 32.41% to -$41.1 million in 2025.
  • Its last three reported values are -$41.1 million in Q3 2025, -$41.7 million for Q2 2025, and -$37.1 million during Q1 2025.